【製薬準大手】がん領域の新薬「オプジーボ」の普及拡大で急成長。
日付 | 信用売残 (解説) | 信用買残 (解説) | 信用倍率 (解説) |
---|---|---|---|
2023/1/20 | 118,600 | 2,110,300 | 17.79 |
2023/1/13 | 130,900 | 2,162,600 | 16.52 |
2023/1/6 | 122,600 | 2,135,400 | 17.42 |
2022/12/30 | 103,500 | 2,040,500 | 19.71 |
2022/12/23 | 96,500 | 1,862,900 | 19.30 |
2022/12/16 | 93,600 | 1,865,200 | 19.93 |
2022/12/9 | 84,800 | 1,862,000 | 21.96 |
2022/12/2 | 83,500 | 1,887,400 | 22.60 |
2022/11/25 | 240,700 | 1,810,300 | 7.52 |
2022/11/18 | 189,300 | 1,874,900 | 9.90 |
2022/11/11 | 79,000 | 1,949,400 | 24.68 |
2022/11/4 | 82,100 | 1,963,900 | 23.92 |
2022/10/28 | 97,700 | 1,899,800 | 19.45 |
2022/10/21 | 40,000 | 1,919,400 | 47.99 |
2022/10/14 | 66,700 | 1,925,500 | 28.87 |
2022/10/7 | 51,300 | 2,000,100 | 38.99 |
2022/9/30 | 44,400 | 2,022,900 | 45.56 |
2022/9/22 | 50,900 | 2,111,000 | 41.47 |
2022/9/16 | 59,100 | 2,103,200 | 35.59 |
2022/9/9 | 81,200 | 2,101,300 | 25.88 |
2022/9/2 | 65,600 | 2,156,100 | 32.87 |
2022/8/26 | 74,800 | 2,202,700 | 29.45 |
2022/8/19 | 88,100 | 2,230,500 | 25.32 |
2022/8/12 | 73,200 | 2,066,500 | 28.23 |
2022/8/5 | 100,900 | 2,051,200 | 20.33 |
2022/7/29 | 198,500 | 1,576,000 | 7.94 |